SG Americas Securities LLC Buys 35,982 Shares of Solventum Corporation $SOLV

SG Americas Securities LLC raised its stake in shares of Solventum Corporation (NYSE:SOLV) by 38.4% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 129,663 shares of the company’s stock after purchasing an additional 35,982 shares during the period. SG Americas Securities LLC owned 0.07% of Solventum worth $8,467,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Strong Tower Advisory Services lifted its stake in shares of Solventum by 4.9% in the first quarter. Strong Tower Advisory Services now owns 112,703 shares of the company’s stock worth $7,360,000 after buying an additional 5,295 shares during the last quarter. Hsbc Holdings PLC grew its stake in Solventum by 2.3% in the 4th quarter. Hsbc Holdings PLC now owns 227,139 shares of the company’s stock valued at $18,021,000 after buying an additional 5,015 shares during the last quarter. Rockefeller Capital Management L.P. grew its stake in Solventum by 15.5% in the 4th quarter. Rockefeller Capital Management L.P. now owns 6,450 shares of the company’s stock valued at $511,000 after buying an additional 864 shares during the last quarter. Corient Private Wealth LLC raised its holdings in Solventum by 18.5% in the 4th quarter. Corient Private Wealth LLC now owns 49,092 shares of the company’s stock worth $3,859,000 after acquiring an additional 7,653 shares during the period. Finally, Bayban bought a new position in Solventum in the 4th quarter worth $134,000.

Solventum Stock Performance

NYSE SOLV opened at $79.56 on Friday. The company has a debt-to-equity ratio of 0.96, a current ratio of 1.07 and a quick ratio of 0.75. The firm has a market capitalization of $13.78 billion, a price-to-earnings ratio of 9.75, a P/E/G ratio of 1.23 and a beta of 0.69. The company’s fifty day moving average is $74.58 and its two-hundred day moving average is $74.62. Solventum Corporation has a 52-week low of $62.38 and a 52-week high of $88.20.

Solventum (NYSE:SOLV) last announced its quarterly earnings data on Tuesday, May 5th. The company reported $1.48 EPS for the quarter, beating analysts’ consensus estimates of $1.35 by $0.13. Solventum had a net margin of 17.33% and a return on equity of 23.51%. The business had revenue of $2.01 billion during the quarter, compared to analyst estimates of $1.97 billion. During the same quarter in the prior year, the business earned $1.34 earnings per share. The firm’s revenue for the quarter was down 3.0% on a year-over-year basis. Solventum has set its FY 2026 guidance at 6.600-6.600 EPS. Equities research analysts forecast that Solventum Corporation will post 6.58 EPS for the current year.

Analysts Set New Price Targets

SOLV has been the topic of several research analyst reports. BTIG Research reaffirmed a “buy” rating and issued a $89.00 price target on shares of Solventum in a research report on Wednesday, May 6th. Stifel Nicolaus cut their price objective on Solventum from $105.00 to $90.00 and set a “buy” rating for the company in a research report on Wednesday, May 6th. Wall Street Zen downgraded Solventum from a “buy” rating to a “hold” rating in a research note on Sunday, March 8th. KeyCorp increased their target price on Solventum from $92.00 to $93.00 and gave the company an “overweight” rating in a research note on Wednesday, May 6th. Finally, Wedbush initiated coverage on Solventum in a report on Friday, May 15th. They issued an “outperform” rating and a $94.00 target price on the stock. Eight research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $84.25.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.